New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;PFE;DUF;CG;HLF;CALM From The Last 14 Days
Check below for free stories on BMY;PFE;DUF;CG;HLF;CALM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
July 22, 2014
19:34 EDTCGJPMorgan in advanced talks to sell half its stake in buyout arm, WSJ says
Subscribe for More Information
16:36 EDTHLFOn The Fly: Closing Wrap
Subscribe for More Information
16:18 EDTPFEPuma Biotech now responsible for R&D expenses associated with legacy trials
Subscribe for More Information
15:49 EDTCGBlackstone to buy majority stake in Service King from Carlyle, WSJ says
Blackstone's (BX) purchase from Carlyle Group (CG) of the majority stake in the repair chain values the company at about $650M, according to The Wall Street Journal, citing a source. Reference Link
15:05 EDTHLFHerbalife says Ackman claim about nutrition clubs' earnings 'false, fabricated'
Subscribe for More Information
15:03 EDTHLFHerbalife says Ackman 'over-promised and under-delivered' with presentation
Subscribe for More Information
14:38 EDTHLFHerbalife CFO says Ackman 'completely misunderstood' Club 100
Subscribe for More Information
14:25 EDTCGBlackstone to buy majority stake in Service King from Carlyle, Dow says
Subscribe for More Information
13:23 EDTHLFAckman says has never met Senator Markey
Subscribe for More Information
13:02 EDTHLFRob Chapman says Herbalife can hit $150 next summer
Subscribe for More Information
12:44 EDTHLFHerbalife volatility decreases on Bill Ackman presentation
Subscribe for More Information
12:29 EDTHLFOn The Fly: Midday Wrap
Subscribe for More Information
12:26 EDTHLFAckman says Canadian government investigating Herbalife
Subscribe for More Information
11:59 EDTHLFAckman estimates nutrition clubs contribute 'enormously' to Herbalife results
Ackman says Herbalife insiders are selling while the company is repurchasing shares. Bill Ackman continues his presentation on Herbalife.
11:25 EDTHLFHerbalife says alleged $12K average Nutrition Club loss 'just false'
Subscribe for More Information
11:20 EDTHLFHerbalife Club 100 relies on deceptive income claims, Pershing alleges
11:07 EDTHLFOptions with increasing implied volatility: HLF JOY PSEC NI
11:03 EDTHLFHerbalife near session highs, up 7.7% as Ackman presentation continues
Subscribe for More Information
10:46 EDTHLFHigh option volume stocks: SBAC KS EDU PII GALT EJ AXL TSEM HLF BCOR
Subscribe for More Information
10:29 EDTHLFAckman estimates Herbalife nutrition clubs lose money for operators
Ackman alleges real purpose of nutrition clubs is recruitment. Pershing's Bill Ackman continues speaking on his Herbalife webcast.
10:11 EDTHLFHerbalife targeting 'bottom of the pyramid,' says Ackman
Subscribe for More Information
09:58 EDTHLFHerbalife July weekly volatility spikes into Bill Ackman presentation
Subscribe for More Information
09:21 EDTHLFHerbalife CFO says has 'complete confidence' in compliance in regulations
Subscribe for More Information
09:18 EDTHLFHerbalife: Economist says U.S. ops 'inconsistent' with pyramid scheme model
Subscribe for More Information
06:31 EDTHLFHerbalife volatility elevated into Bill Ackman presentation
Subscribe for More Information
05:53 EDTHLFStocks with implied volatility movement; HLF MSFT
Subscribe for More Information
July 21, 2014
15:26 EDTHLFAckman says Herbalife presentation will probe nutrition clubs
Subscribe for More Information
14:45 EDTHLFHerbalife releases new video highlighting 'positive impact' of nutrition clubs
Subscribe for More Information
14:02 EDTHLFHerbalife falls after Ackman teases presentation on coming 'collapse'
Subscribe for More Information
13:55 EDTHLFIcahn has not sold 'single share' of Herbalife, Gasparino says
"Sources tell @FoxBusiness uncle @Carl_C_Icahn has not sold a single $hlf share," Fox Business' Charles Gasparino stated on Twitter. Reference Link
13:45 EDTHLFHerbalife puts active ahead of Bill Ackman presentation
Subscribe for More Information
13:04 EDTHLFHerbalife spikes lower on Ackman comments, levels to watch
Shares are down over 6.3% to $56.92 at time of writing after Bill Ackman stated that he was going to expose an "incredible fraud" tomorrow at 10am ET, detailing why he believes the company will collapse. At current price next support is at $56.18, the low of the day. Resistance is at $57.91.
12:51 EDTHLFHerbalife sinks 6% after Ackman says presentation will detail collapse
12:49 EDTHLFAckman says going to expose 'incredible fraud' tomorrow
Subscribe for More Information
12:48 EDTHLFAckman says Herbalife presentation tomorrow most important of career
Subscribe for More Information
12:46 EDTHLFAckman says Herbalife presentation will show why company will collapse
Bill Ackman of Pershing Square is speaking on CNBC.
06:43 EDTBMYGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 18, 2014
09:01 EDTHLFHerbalife says independent members 'demand opponents stop lies and smears'
Subscribe for More Information
07:14 EDTCGBlackstone, KKR, TPG discussing deal collusion suit settlement, Reuters says
Blackstone (BX), KKR (KKR) and TPG Capital are in discussions to settle a U.S. case accusing the firms of conspiring not to outbid one another and other buyout companies on takeovers of firms, according to Reuters, citing two people familiar with the matter. If all three companies settled, the Carlyle Group (CG) would be the only private equity company still up against a trial among 11 firms originally accused of colluding in agreements before the financial crisis occurred. Reference Link
July 17, 2014
13:47 EDTHLFHerbalife says 'confident' will overcome Pershing's 'campaign of misinformation'
Subscribe for More Information
13:47 EDTHLFHerbalife says Pershing Square's campaign 'based on propaganda'
Subscribe for More Information
13:46 EDTHLFHerbalife says 'stands behind quality' of products
Herbalife issued the following statement regarding the strength and integrity of its business: "Herbalife has the utmost trust in the integrity of our business model and that we are in compliance with all applicable laws and regulations. We are cooperating fully with the FTC and welcome the opportunity to clear up misinformation in the marketplace. Herbalife stands behind the quality of our products and our commitment to member satisfaction and consumer protection. Herbalife continues to face an unprecedented and unrelenting attack from Pershing Square to support its $1B bet to manipulate and drive Herbalife's stock price to zero to the detriment of our investors, members, customers and employees. Herbalife is confident that the facts are on its side and that it will overcome Pershing Square's campaign of misinformation about the Company as the truth about Pershing Square's increasingly desperate accusations is revealed. Attacks on Herbalife have been clearly orchestrated by Pershing Square and its agents. Pershing Square's attack on the Company lacks any impartiality or accountability. Pershing Square has no duty to any member of the public and is unhindered by the disclosure obligations imposed upon publicly traded corporations. With Pershing Square's limited accountability, in light of the historical regulatory scrutiny placed on Herbalife, it has made the astonishing claim that it is a "provable certainty" Herbalife is a massive, sprawling fraud that had gone undetected for more than 30 years. Pershing Square is claiming that decades of Herbalife management, and a material number of members had all kept this secret.Pershing Square has admittedly spent more than $20B and 18 months trying to find former Herbalife members from as far back as 2008 that will complain about their experience with the Company. In fact, Pershing Square has even been willing to pay multi-million dollar bounties to anyone willing to generate negative publicity against Herbalife and support Pershing Square's agenda. The reason why Pershing Square has so few relative voices is because, as demonstrated through third party studies, the overwhelming majority of our members have been very satisfied, and we are proud of that track record. In fact, Pershing Square's own well-financed campaign to find dissatisfied customers has actually largely validated our consumer reputation. Ultimately, Pershing Square's campaign is based on propaganda."
11:56 EDTHLFPershing Square to reveal investigation into Herbalife Nutrition Clubs
Subscribe for More Information
08:08 EDTBMY, PFEBristol-Myers, Pfizer announce enrollment in Phase IV EMANATE trial for Eliquis
Subscribe for More Information
05:53 EDTHLFStocks with implied volatility movement; HLF ABBV
Stocks with implied volatility movement; Herbalife (HLF) 52, AbbVie (ABBV) 30 according to iVolatility.
July 16, 2014
18:26 EDTHLFOn The Fly: After Hours Movers
Subscribe for More Information
17:44 EDTHLFAckman says he would like Icahn out of Herbalife holdings
17:17 EDTHLFIcahn says bad time to talk about Herbalife, but hasn't sold one share
Subscribe for More Information
11:46 EDTHLFHerbalife August volatility flat into Q2
Subscribe for More Information
10:59 EDTHLFHerbalife August volatility flat on into Q2
Subscribe for More Information
10:36 EDTPFETreasury calls on Congress to halt inversion deals
Subscribe for More Information
10:17 EDTHLFAckman to detail Herbalife club probe next week, NY Post says
Subscribe for More Information
09:27 EDTPFEPfizer to acquire InnoPharma for upfront cash payment of $225M
Subscribe for More Information
07:59 EDTPFETreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:04 EDTPFEPfizer says primary endpoint met in Phase 3 study of BeneFIX
Pfizer announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B. The top-line results of the study showed that the primary study endpoint was met and hemophilia B patients taking once-weekly BeneFIX showed a statistically significant reduction in the annualized bleeding rate relative to on-demand treatment with BeneFIX. In the study, the median ABR value, a commonly used measure of efficacy for prophylaxis regimens in hemophilia, was 2.0 for the prophylaxis regimen, compared to 33.6 for the on-demand regimen, representing a 94% decrease in bleeding rates. The mean ABR value was 3.6 for the prophylaxis period, compared to 32.9 for the on-demand treatment, which represents a reduction of 89%. Study results also showed that prophylaxis treatment significantly reduced both spontaneous and traumatic ABR compared to on-demand treatment with BeneFIX. In addition to meeting the primary endpoint, the secondary study endpoints showed that none of the 1,254 prophylaxis infusions administered during the study were associated with a less than expected therapeutic effect occurrence, which was defined as a spontaneous bleed occurring within 48 hours of a prophylaxis infusion. These results are preliminary, top-line data and are subject to additional analyses. Complete results from this study will be submitted for presentation at upcoming medical congresses and submitted for publication in a peer-reviewed journal.
06:26 EDTBMYBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
July 15, 2014
11:13 EDTBMYPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
07:35 EDTBMYPerrigo potential buyers list could be limited, says Jefferies
After Globes reported that Perrigo retained an investment bank to assist with a potential merger, Jefferies says the list of potential buyers could be limited since the store brand business is fundamentally a high volume, lower margin model. The firm notes U.S. companies that currently do not have large over-the-counter divisions include Bristol-Myers (BMY), Eli Lilly (LLY) and Merck (MRK). Jefferies views the merger speculation surrounding Perrigo as not surprising given the company's strong long-term fundamentals and attractive Irish domicile. It has a Buy rating on the stock with a $160 price target.
July 10, 2014
14:15 EDTHLFHerbalife p.r. flurry 'smells of desperation,' Seeking Alpha contributor says
Herbalife, in an effort to inform investors that 21 independent members are traveling to Washington D.C. in support of the company, released six nearly identical press releases this morning, as noted by Seeking Alpha contributor "Quoth the Raven." Putting the news out in this way, via six press releases instead of "one, concise release is unprofessional and farcical - it smells of desperation for positive press," according to the author, who disclosed a short position in the stock. Reference Link
12:43 EDTBMYBristol-Myers announces plans for Q3 submission of Opdivo BLA
Bristol-Myers Squibb announced earlier that, following discussions with the FDA, the company is planning a Q3 submission of a Biologics Licensing Application for Opdivo for previously treated advanced melanoma. This will mark the second tumor type for which Bristol-Myers Squibb has a regulatory submission underway for Opdivo in the U.S. “We continue to collaborate closely with the FDA on Opdivo and the planned submission in advanced melanoma represents an important step forward in our company’s commitment to deliver innovative treatment options for patients with cancer,” said Michael Giordano, MD, Head of Oncology Development, Bristol-Myers Squibb. The advanced melanoma BLA is based on data from Checkmate -037, a multinational, multicenter, randomized open-label Phase 3 trial evaluating Opdivo compared to dacarbazine or carboplatin/paclitaxel in patients with unresectable or metastatic melanoma who have been previously treated with Yervoy and, if BRAF-mutation positive, a BRAF inhibitor regimen. Bristol-Myers Squibb has proposed the name Opdivo, which, if approved by health authorities, will serve as the trade name for nivolumab.
11:21 EDTCGInternational Game Technology rises as GTECH reportedly prepares bid
Subscribe for More Information
July 9, 2014
16:04 EDTCALMCal-Maine Foods announces annual sales of over 1B dozen eggs
Subscribe for More Information
10:02 EDTCGOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Advanced Energy (AEIS) downgraded to Neutral from Buy at Dougherty... Apollo Global (APO) downgraded to Neutral from Buy at Citigroup... Artisan Partners (APAM) downgraded to Neutral from Buy at Citigroup... Autoliv (ALV) downgraded to Hold from Buy at Nordea... BNP Paribas (BNPQY) downgraded to Neutral from Overweight at JPMorgan... BP (BP) downgraded to Hold from Buy at Deutsche Bank... Carlyle Group (CG) downgraded to Neutral from Buy at Citigroup... Coach (COH) downgraded at Buckingham... Cummins (CMI) downgraded to Buy from Conviction Buy at Goldman... Garmin (GRMN) downgraded to Underperform from Sector Perform at Pacific Crest... Gigamon (GIMO) downgraded to Buy from Strong Buy at Needham... International Paper (IP) downgraded at RBC Capital... Louisiana-Pacific (LPX) downgraded at RBC Capital... Marvell (MRVL) downgraded to Underperform from Perform at Oppenheimer... McGraw Hill Financial (MHFI) downgraded to Market Perform at Raymond James... Moody's (MCO) downgraded to Market Perform from Outperform at Raymond James... Plum Creek Timber (PCL) downgraded at RBC Capital... Potash (POT) downgraded to Neutral from Overweight at JPMorgan... RGS Energy (RGSE) downgraded at Cowen... Taminco (TAM) downgraded to Neutral from Buy at Citigroup... Total (TOT) downgraded to Hold from Buy at Societe Generale... Unilever (UN) downgraded to Reduce from Neutral at Nomura... VMware (VMW) downgraded to Market Perform from Outperform at Wells Fargo... Vectren (VVC) downgraded to Hold from Buy at KeyBanc.
06:49 EDTPFEPfizer given dismissal of U.S. investor class action before trial, Reuters says
Subscribe for More Information
06:19 EDTCGCarlyle Group downgraded to Neutral from Buy at Citigroup
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use